Anna M Pietroboni

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7917375/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. Multiple Sclerosis Journal, 2022, 28, 1034-1040.	1.4	37
2	Caregiver Tele-Assistance for Reduction of Emotional Distress During the COVID-19 Pandemic. Psychological Support to Caregivers of People with Dementia: The Italian Experience. Journal of Alzheimer's Disease, 2022, 85, 1045-1052.	1.2	7
3	Association of Superficial White Matter Alterations with Cerebrospinal Fluid Biomarkers and Cognitive Decline in Neurodegenerative Dementia. Journal of Alzheimer's Disease, 2022, 85, 431-442.	1.2	2
4	Unravelling the Association Between Amyloid-PET and Cerebrospinal Fluid Biomarkers in the Alzheimer's Disease Spectrum: Who Really Deserves an A+?. Journal of Alzheimer's Disease, 2022, 85, 1009-1020.	1.2	5
5	Amyloid PET imaging and dementias: potential applications in detecting and quantifying early white matter damage. Alzheimer's Research and Therapy, 2022, 14, 33.	3.0	9
6	miR-150-5p and let-7b-5p in Blood Myeloid Extracellular Vesicles Track Cognitive Symptoms in Patients with Multiple Sclerosis. Cells, 2022, 11, 1551.	1.8	8
7	Role of Chitinase 3–like 1 as a Biomarker in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	17
8	Facing the digital divide into a dementia clinic during COVID-19 pandemic: caregiver age matters. Neurological Sciences, 2021, 42, 1247-1251.	0.9	47
9	Detection of the SQSTM1 Mutation in a Patient with Early-Onset Hippocampal Amnestic Syndrome. Journal of Alzheimer's Disease, 2021, 79, 477-481.	1.2	2
10	Clinical features and disease course of patients with acute ischaemic stroke just before the Italian index case: Was COVID-19 already there?. Internal and Emergency Medicine, 2021, 16, 1247-1252.	1.0	0
11	Diogenes syndrome in dementia: a case report. BJPsych Open, 2021, 7, e43.	0.3	0
12	DMTs and Covidâ€19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8, 1738-1744.	1.7	86
13	Distinct patterns of MRI lesions in MOG antibody disease and AQP4 NMOSD: a systematic review and meta-analysis. Multiple Sclerosis and Related Disorders, 2021, 54, 103118.	0.9	5
14	Niemann-Pick Type C 1 (NPC1) and NPC2 Gene Variability in Demented Patients with Evidence of Brain Amyloid Deposition. Journal of Alzheimer's Disease, 2021, 83, 1313-1323.	1.2	5
15	Osmotic demyelination syndrome and leukoencephalopathy in FGF23-related hypophosphatemia: a case report. Neurological Sciences, 2021, 42, 2549-2551.	0.9	0
16	Low CSF β-amyloid levels predict early regional grey matter atrophy in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 39, 101899.	0.9	5
17	CSF β-amyloid predicts early cerebellar atrophy and is associated with a poor prognosis in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 37, 101462.	0.9	5
18	Parieto-occipital sulcus widening differentiates posterior cortical atrophy from typical Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102453.	1.4	11

Anna M Pietroboni

#	Article	IF	CITATIONS
19	The Role of Amyloid-β in White Matter Damage: Possible Common Pathogenetic Mechanisms in Neurodegenerative and Demyelinating Diseases. Journal of Alzheimer's Disease, 2020, 78, 13-22.	1.2	15
20	Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression. Multiple Sclerosis Journal, 2020, 26, 1268-1269.	1.4	35
21	Evidence of retinal anterograde neurodegeneration in the very early stages of multiple sclerosis: a longitudinal OCT study. Neurological Sciences, 2020, 41, 3175-3183.	0.9	16
22	CSF β-amyloid predicts prognosis in patients with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1223-1231.	1.4	19
23	Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes. Alzheimer's Research and Therapy, 2019, 11, 84.	3.0	28
24	Monozygotic Twins with Frontotemporal Dementia Due To Thr272fs GRN Mutation Discordant for Age At Onset. Journal of Alzheimer's Disease, 2019, 67, 1173-1179.	1.2	4
25	Inflammatory expression profile in peripheral blood mononuclear cells from patients with Nasu-Hakola Disease. Cytokine, 2019, 116, 115-119.	1.4	6
26	Cerebrospinal Fluid Level of Aquaporin4: A New Window on Glymphatic System Involvement in Neurodegenerative Disease?. Journal of Alzheimer's Disease, 2019, 69, 663-669.	1.2	21
27	Amyloid PET as a marker of normal-appearing white matter early damage in multiple sclerosis: correlation with CSF β-amyloid levels and brain volumes. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 280-287.	3.3	28
28	Structural and metabolic cerebral alterations between elderly bipolar disorder and behavioural variant frontotemporal dementia: A combined MRI-PET study. Australian and New Zealand Journal of Psychiatry, 2019, 53, 413-423.	1.3	18
29	The loss of macular ganglion cells begins from the early stages of disease and correlates with brain atrophy in multiple sclerosis patients. Multiple Sclerosis Journal, 2019, 25, 31-38.	1.4	39
30	CSF β-amyloid and white matter damage: a new perspective on Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 352-357.	0.9	36
31	Behavioral and Neurophysiological Effects of Transcranial Direct Current Stimulation (tDCS) in Fronto-Temporal Dementia. Frontiers in Behavioral Neuroscience, 2018, 12, 235.	1.0	19
32	LncRNAs expression profile in peripheral blood mononuclear cells from multiple sclerosis patients. Journal of Neuroimmunology, 2018, 324, 129-135.	1.1	37
33	Distinct patterns of brain atrophy in Genetic Frontotemporal Dementia Initiative (GENFI) cohort revealed by visual rating scales. Alzheimer's Research and Therapy, 2018, 10, 46.	3.0	34
34	Recognition of viral and self-antigens by T H 1 and T H 1/T H 17 central memory cells in patients with multiple sclerosis reveals distinct roles in immune surveillance and relapses. Journal of Allergy and Clinical Immunology, 2017, 140, 797-808.	1.5	59
35	Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod. Journal of the Neurological Sciences, 2017, 381, 296-297.	0.3	4
36	Evidence of CNS β-amyloid deposition in Nasu-Hakola disease due to the <i>TREM2</i> Q33X mutation. Neurology, 2017, 89, 2503-2505.	1.5	26

Anna M Pietroboni

#	Article	IF	CITATIONS
37	Word and Picture Version of the Free and Cued Selective Reminding Test (FCSRT): Is There Any Difference?. Journal of Alzheimer's Disease, 2017, 61, 47-52.	1.2	8
38	CSF β-amyloid as a putative biomarker of disease progression in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1085-1091.	1.4	33
39	Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis. Journal of Neuroimmunology, 2016, 299, 81-83.	1.1	39
40	Balò's concentric sclerosis: still to be considered as a variant of multiple sclerosis?. Neurological Sciences, 2015, 36, 2277-2280.	0.9	7
41	The Novel GRN g.1159_1160delTG Mutation is Associated with Behavioral Variant Frontotemporal Dementia. Journal of Alzheimer's Disease, 2015, 44, 277-282.	1.2	7
42	Usefulness of Multi-Parametric MRI for the Investigation of Posterior Cortical Atrophy. PLoS ONE, 2015, 10, e0140639.	1.1	4
43	Partial recovery after severe immune reconstitution inflammatory syndrome in a multiple sclerosis patient with progressive multifocal leukoencephalopathy. Immunotherapy, 2014, 6, 23-28.	1.0	3
44	Brain temperature in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 894-896.	1.4	3
45	C9ORF72 repeat expansion not detected in patients with multiple sclerosis. Neurobiology of Aging, 2014, 35, 1213.e1-1213.e2.	1.5	6
46	P3-104: A NOVEL MUTATION IN PROGRANULIN GENE IN BEHAVIOURAL VARIANT FRONTO-TEMPORAL DEMENTIA. , 2014, 10, P666-P666.		0
47	Expression and Genetic Analysis of MicroRNAs Involved in Multiple Sclerosis. International Journal of Molecular Sciences, 2013, 14, 4375-4384.	1.8	71
48	Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1938-1942.	1.4	98
49	A 66-year-old patient with vanishing white matter disease due to the p.Ala87Val <i>EIF2B3</i> mutation. Neurology, 2012, 79, 2077-2078.	1.5	16
50	Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. BMC Neurology, 2012, 12, 7.	0.8	50
51	Early Onset Behavioral Variant Frontotemporal Dementia due to the C9ORF72 Hexanucleotide Repeat Expansion: Psychiatric Clinical Presentations. Journal of Alzheimer's Disease, 2012, 31, 447-452.	1.2	60
52	Sciatic endometriosis presenting as periodic (catamenial) sciatic radiculopathy. Journal of Neurology, 2012, 259, 1470-1471.	1.8	12
53	Phenotypic Heterogeneity of the GRN Asp22fs Mutation in a Large Italian Kindred. Journal of Alzheimer's Disease, 2011, 24, 253-259.	1.2	62
54	A Novel MAPT Mutation Associated with the Clinical Phenotype of Progressive Nonfluent Aphasia. Journal of Alzheimer's Disease, 2011, 26, 19-26.	1.2	28

#	Article	IF	CITATIONS
55	Cerebrospinal fluid progranulin levels in patients with different multiple sclerosis subtypes. Neuroscience Letters, 2010, 469, 234-236.	1.0	24
56	Teaching Neuroimage: Crowned Dens Syndrome, an Acute Attack of Calcium Pyrophosphate Deposition Disease Mimicking Acute Meningitis. Neurology, 0, , 10.1212/WNL.0000000000200949.	1.5	0